Landos Biopharma's Crohn's disease, ulcerative colitis drug well-tolerated — 3 insights

A phase 1 clinical trial found that Landos Biopharma's Crohn's disease and ulcerative colitis treatment, BT-11, was well-tolerated with no dose-limiting toxicities or detectable systemic immunosuppression.

What you should know:

1. Researchers tested BT-11 in 70 patients as either a single-ascending dose or as a seven-day multiple-ascending dose.

2. Fecal concentrations of BT-11 were 6,000 times higher than maximum plasma concentrations. Researchers said the increased concentrations mirrored what they observed in preclinical animal tests.

3. Landos will explore the seven-day, 14 milligram dosage in a phase 2 clinical trial.

More articles on gastroenterology:
3 things to know about outpatient cervical disc replacement
10 things to know about spine surgery for ASCs in 2019
Outpatient revision minimally invasive lumbar decompression: 4 notes on ASC vs. HOPD  

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast